| Dr Alfredo Emilio Conde, MD | |
|
8038 Wurzbach Rd Ste 210, San Antonio, TX 78229-3812 | |
| (210) 614-4337 | |
| (210) 614-4357 |
| Full Name | Dr Alfredo Emilio Conde |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 37 Years |
| Location | 8038 Wurzbach Rd Ste 210, San Antonio, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194803585 | NPI | - | NPPES |
| 0967523-02 | Medicaid | TX | |
| 110178629 | Other | TX | RRMC |
| 0048DH | Other | TX | BLUECROSS |
| 096752305 | Medicaid | TX | |
| 110682102 | Other | TX | FIRSTCARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | J9647 (Texas) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | J9647 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Methodist Hospital | San antonio, TX | Hospital |
| Entity Name | Christus Trinity Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285684225 PECOS PAC ID: 3072426741 Enrollment ID: O20031204001091 |
News Archive
Statins, a class of drugs used to lower cholesterol levels, have been successfully fighting heart disease for years. A new study from Tel Aviv University has now found that the same drugs cut the risks of cataracts in men by almost 40%.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.
In a research paper recently uploaded to the preprint server medRxiv* by Schrezenmeier et al. (August 12th, 2021) the potential benefit of three vaccine doses in either a homogenous or heterogeneous dosing regimen amongst kidney transplant patients is assessed, finding that the search for viable vaccination approaches amongst these patients remains an urgent medical need.
Cepheid announced today that it has filed an answer and counterclaims in a patent suit brought by Abaxis on June 28, 2010 in the United States District Court for the Northern District of California. In its filing, Cepheid denied Abaxis' allegations of patent infringement, asked the Court to determine it has paid all royalties due and is in full compliance with all the terms of its license, and to find that Abaxis' patents are invalid.
The unchecked advance of COVID-19 has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: SARS-CoV-2. An encouraging new study shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies.
› Verified 2 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629307095 PECOS PAC ID: 3476688318 Enrollment ID: O20100317001021 |
News Archive
Statins, a class of drugs used to lower cholesterol levels, have been successfully fighting heart disease for years. A new study from Tel Aviv University has now found that the same drugs cut the risks of cataracts in men by almost 40%.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.
In a research paper recently uploaded to the preprint server medRxiv* by Schrezenmeier et al. (August 12th, 2021) the potential benefit of three vaccine doses in either a homogenous or heterogeneous dosing regimen amongst kidney transplant patients is assessed, finding that the search for viable vaccination approaches amongst these patients remains an urgent medical need.
Cepheid announced today that it has filed an answer and counterclaims in a patent suit brought by Abaxis on June 28, 2010 in the United States District Court for the Northern District of California. In its filing, Cepheid denied Abaxis' allegations of patent infringement, asked the Court to determine it has paid all royalties due and is in full compliance with all the terms of its license, and to find that Abaxis' patents are invalid.
The unchecked advance of COVID-19 has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: SARS-CoV-2. An encouraging new study shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies.
› Verified 2 days ago
| Entity Name | Sundance Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326490889 PECOS PAC ID: 1153602016 Enrollment ID: O20170109000714 |
News Archive
Statins, a class of drugs used to lower cholesterol levels, have been successfully fighting heart disease for years. A new study from Tel Aviv University has now found that the same drugs cut the risks of cataracts in men by almost 40%.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.
In a research paper recently uploaded to the preprint server medRxiv* by Schrezenmeier et al. (August 12th, 2021) the potential benefit of three vaccine doses in either a homogenous or heterogeneous dosing regimen amongst kidney transplant patients is assessed, finding that the search for viable vaccination approaches amongst these patients remains an urgent medical need.
Cepheid announced today that it has filed an answer and counterclaims in a patent suit brought by Abaxis on June 28, 2010 in the United States District Court for the Northern District of California. In its filing, Cepheid denied Abaxis' allegations of patent infringement, asked the Court to determine it has paid all royalties due and is in full compliance with all the terms of its license, and to find that Abaxis' patents are invalid.
The unchecked advance of COVID-19 has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: SARS-CoV-2. An encouraging new study shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies.
› Verified 2 days ago
| Entity Name | Alfredo Conde Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821586454 PECOS PAC ID: 3779830666 Enrollment ID: O20180724001435 |
News Archive
Statins, a class of drugs used to lower cholesterol levels, have been successfully fighting heart disease for years. A new study from Tel Aviv University has now found that the same drugs cut the risks of cataracts in men by almost 40%.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.
In a research paper recently uploaded to the preprint server medRxiv* by Schrezenmeier et al. (August 12th, 2021) the potential benefit of three vaccine doses in either a homogenous or heterogeneous dosing regimen amongst kidney transplant patients is assessed, finding that the search for viable vaccination approaches amongst these patients remains an urgent medical need.
Cepheid announced today that it has filed an answer and counterclaims in a patent suit brought by Abaxis on June 28, 2010 in the United States District Court for the Northern District of California. In its filing, Cepheid denied Abaxis' allegations of patent infringement, asked the Court to determine it has paid all royalties due and is in full compliance with all the terms of its license, and to find that Abaxis' patents are invalid.
The unchecked advance of COVID-19 has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: SARS-CoV-2. An encouraging new study shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies.
› Verified 2 days ago
| Entity Name | Hni Physician Services Of Texas Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538729744 PECOS PAC ID: 5092128710 Enrollment ID: O20210119000838 |
News Archive
Statins, a class of drugs used to lower cholesterol levels, have been successfully fighting heart disease for years. A new study from Tel Aviv University has now found that the same drugs cut the risks of cataracts in men by almost 40%.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.
In a research paper recently uploaded to the preprint server medRxiv* by Schrezenmeier et al. (August 12th, 2021) the potential benefit of three vaccine doses in either a homogenous or heterogeneous dosing regimen amongst kidney transplant patients is assessed, finding that the search for viable vaccination approaches amongst these patients remains an urgent medical need.
Cepheid announced today that it has filed an answer and counterclaims in a patent suit brought by Abaxis on June 28, 2010 in the United States District Court for the Northern District of California. In its filing, Cepheid denied Abaxis' allegations of patent infringement, asked the Court to determine it has paid all royalties due and is in full compliance with all the terms of its license, and to find that Abaxis' patents are invalid.
The unchecked advance of COVID-19 has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: SARS-CoV-2. An encouraging new study shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alfredo Emilio Conde, MD 8038 Wurzbach Rd Ste 210, San Antonio, TX 78229-3812 Ph: (210) 614-4337 | Dr Alfredo Emilio Conde, MD 8038 Wurzbach Rd Ste 210, San Antonio, TX 78229-3812 Ph: (210) 614-4337 |
News Archive
Statins, a class of drugs used to lower cholesterol levels, have been successfully fighting heart disease for years. A new study from Tel Aviv University has now found that the same drugs cut the risks of cataracts in men by almost 40%.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.
In a research paper recently uploaded to the preprint server medRxiv* by Schrezenmeier et al. (August 12th, 2021) the potential benefit of three vaccine doses in either a homogenous or heterogeneous dosing regimen amongst kidney transplant patients is assessed, finding that the search for viable vaccination approaches amongst these patients remains an urgent medical need.
Cepheid announced today that it has filed an answer and counterclaims in a patent suit brought by Abaxis on June 28, 2010 in the United States District Court for the Northern District of California. In its filing, Cepheid denied Abaxis' allegations of patent infringement, asked the Court to determine it has paid all royalties due and is in full compliance with all the terms of its license, and to find that Abaxis' patents are invalid.
The unchecked advance of COVID-19 has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: SARS-CoV-2. An encouraging new study shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies.
› Verified 2 days ago
Dr. Dennis Anthony Ruff, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 8307 Gault Ln, San Antonio, TX 78209 Phone: 210-798-5112 | |
Zarema J Singson, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 5223 Hamilton Wolfe Rd, San Antonio, TX 78229 Phone: 210-614-1234 Fax: 210-614-0952 | |
Sapna Raghunathan, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 8300 Floyd Curl Dr, San Antonio, TX 78229 Phone: 210-450-9490 Fax: 210-450-6065 | |
Dr. Jonathan Edward Slovik, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4502 Medical Dr, San Antonio, TX 78229 Phone: 210-358-4000 Fax: 210-358-0647 | |
Mr. Paul Joseph Fanucchi, NP Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: Marianist Residence, 520 Fondham, San Antonio, TX 78228 Phone: 210-434-4157 Fax: 210-433-6005 | |
Socrates B Aramburu, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1100 Mccullough Ave, Suite 300, San Antonio, TX 78212 Phone: 210-271-3204 Fax: 210-222-2761 | |
David H White, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 6800 Ih 10 W, Ste 350, San Antonio, TX 78201 Phone: 210-616-0801 |